Literature DB >> 11854916

Taxotere resistance in SUIT Taxotere resistance in pancreatic carcinoma cell line SUIT 2 and its sublines.

B Liu1, E Staren, T Iwamura, H Appert, J Howard.   

Abstract

AIM: To investigate the specific mechanisms of intrinsic and acquired resistance to taxotere (TXT) in pancreatic adenocarcinoma (PAC).
METHODS: MTT assay was used to detect the sensitivity of PAC cell line SUIT-2 and its sublines (S-007, S-013, S-020, S-028 and TXT selected SUIT-2 cell line, S2/TXT) to TXT. Mdr1 (P-gp), multidrug resistance associated protein (MRP), lung resistance protein (LRP) and beta-tubulin isotype gene expressions were detected by RT-PCR. The functionality of P-gp and MRP was tested using their specific blocker verapamil (Ver) and indomethacin (IMC), respectively. The transporter activity of P-gp was also confirmed by Rhodamine 123 accumulation assay.
RESULTS: S-020 and S2/TXT were found to be significantly resistant to TXT(19 and 9.5-fold to their parental cell line SUIT-2, respectively). RT-PCR demonstrated strong expression of Mdr1 in these two cell lines, but weaker expression or no expression in other cells lines. MRP and LRP expressions were found in most of these cell lines. The TXT-resistance in S2-020 and S2/TXT could be reversed almost completely by Ver, but not by IMC. Flow cytometry showed that Ver increased the accumulation of Rhodamine-123 in these two cell lines. Compared with S-020 and SUIT-2, the levels of beta-tubulin isotype II, III expressions in S-2/TXT were increased remarkably.
CONCLUSION: The both intrinsic and acquired TXT-related drug resistance in these PAC cell lines is mainly mediated by P-gp, but had no relationship to MRP and LRP expressions. The increases of beta-tubulin isotype II, III might be collateral changes that occur when the SUIT-2 cells are treated with TXT.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11854916      PMCID: PMC4695609          DOI: 10.3748/wjg.v7.i6.855

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  52 in total

1.  Docetaxel chemotherapy for pancreatic cancer: Do results support certainty? Italian Group for the Study of Gastrointestinal Tract Carcinomas.

Authors:  F Graziano; S Cascinu
Journal:  J Clin Oncol       Date:  2000-01       Impact factor: 44.544

2.  Expression of lung resistance protein in patients with gastric carcinoma and its clinical significance.

Authors:  Zhong-Min Liu; Nan-Hai Shou; Xi-Hong Jiang
Journal:  World J Gastroenterol       Date:  2000-06       Impact factor: 5.742

3.  Overexpression of P-glycoprotein in hepatocellular carcinoma and its clinical implication.

Authors:  Xian-Bing Kong; Zu-Kui Yang; Li-Jian Liang; Jie-Fu Huang; Han-Liang Lin
Journal:  World J Gastroenterol       Date:  2000-02       Impact factor: 5.742

Review 4.  Integration of new chemotherapeutic agents into chemoradiotherapy for stage III non--small cell lung cancer: focus on docetaxel.

Authors:  D R Gandara; P N Lara; Z Goldberg; D H Lau
Journal:  Semin Oncol       Date:  2001-06       Impact factor: 4.929

Review 5.  A systematic overview of chemotherapy effects in pancreatic cancer.

Authors:  J Permert; L Hafström; P Nygren; B Glimelius
Journal:  Acta Oncol       Date:  2001       Impact factor: 4.089

6.  Expression of multidrug resistance-related markers in gastric cancer.

Authors:  K Fan; D Fan; L F Cheng; C Li
Journal:  Anticancer Res       Date:  2000 Nov-Dec       Impact factor: 2.480

7.  Microtubules in Plasmodium falciparum merozoites and their importance for invasion of erythrocytes.

Authors:  R E Fowler; R E Fookes; F Lavin; L H Bannister; G H Mitchell
Journal:  Parasitology       Date:  1998-11       Impact factor: 3.234

8.  PAK-104P, a pyridine analogue, reverses paclitaxel and doxorubicin resistance in cell lines and nude mice bearing xenografts that overexpress the multidrug resistance protein.

Authors:  U Vanhoefer; S Cao; H Minderman; K Tóth; R J Scheper; M L Slovak; Y M Rustum
Journal:  Clin Cancer Res       Date:  1996-02       Impact factor: 12.531

9.  Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Cooperative Group of Docetaxel for Pancreatic Cancer in Japan.

Authors:  S Okada; Y Sakata; S Matsuno; M Kurihara; Y Sasaki; Y Ohashi; T Taguchi
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

10.  Differentiation of human colon cancer cells changes the expression of beta-tubulin isotypes and MAPs.

Authors:  G Carles; D Braguer; C Dumontet; V Bourgarel; A Gonçalves; M Sarrazin; J B Rognoni; C Briand
Journal:  Br J Cancer       Date:  1999-06       Impact factor: 7.640

View more
  10 in total

1.  Localization of TRAIL/TRAILR in fetal pancreas.

Authors:  Li-Hua Chen; Xue-Song Liu; Wen-Yong Wang; Wei-Ning Han; Bo-Rong Pan; Bo-Quan Jin
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

Review 2.  Microtubule targeting agents: from biophysics to proteomics.

Authors:  D Calligaris; P Verdier-Pinard; F Devred; C Villard; D Braguer; Daniel Lafitte
Journal:  Cell Mol Life Sci       Date:  2010-01-28       Impact factor: 9.261

Review 3.  Microtubules and resistance to tubulin-binding agents.

Authors:  Maria Kavallaris
Journal:  Nat Rev Cancer       Date:  2010-02-11       Impact factor: 60.716

4.  Correlation of CT enhancement, tumor angiogenesis and pathologic grading of pancreatic carcinoma.

Authors:  Zhong-Qiu Wang; Jie-Shou Li; Guang-Ming Lu; Xin-Hua Zhang; Zi-Qian Chen; Kui Meng
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

5.  Inhibitory effects of docetaxel on expression of VEGF, bFGF and MMPs of LS174T cell.

Authors:  Xue-Liang Guo; Geng-Jin Lin; Hong Zhao; Yong Gao; Li-Ping Qian; San-Rong Xu; Li-Na Fu; Qing Xu; Jie-Jun Wang
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

6.  Subcellular daunorubicin distribution and its relation to multidrug resistance phenotype in drug-resistant cell line SMMC-7721/R.

Authors:  Jia-Yin Yang; Hua-You Luo; Qi-Yuan Lin; Zi-Ming Liu; Lu-Nan Yan; Ping Lin; Jie Zhang; Shong Lei
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

Review 7.  [Biomarkers - the way towards individualized chemotherapy in non-small cell lung cancer (NSCLC)].

Authors:  Sabine Danzinger; Martin Filipits
Journal:  Wien Med Wochenschr       Date:  2007

8.  K-ras gene mutation in the diagnosis of ultrasound guided fine-needle biopsy of pancreatic masses.

Authors:  Min Zheng; Lian-Xin Liu; An-Long Zhu; Shu-Yi Qi; Hong-Chi Jiang; Zhu-Ying Xiao
Journal:  World J Gastroenterol       Date:  2003-01       Impact factor: 5.742

9.  TUBB3 overexpression has a negligible effect on the sensitivity to taxol in cultured cell lines.

Authors:  Mihoko A Tame; Anna G Manjón; Daria Belokhvostova; Jonne A Raaijmakers; René H Medema
Journal:  Oncotarget       Date:  2017-05-10

10.  Nanoformulation design and therapeutic potential of a novel tubulin inhibitor in pancreatic cancer.

Authors:  Rajan Sharma Bhattarai; Virender Kumar; Svetlana Romanova; Jitender Bariwal; Hao Chen; Shanshan Deng; Vijaya R Bhatt; Tatiana Bronich; Wei Li; Ram I Mahato
Journal:  J Control Release       Date:  2020-09-30       Impact factor: 9.776

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.